Literature DB >> 17167121

N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients.

Angela Yee-Moon Wang1, Christopher Wai-Kei Lam, Cheuk-Man Yu, Mei Wang, Iris Hiu-Shuen Chan, Yan Zhang, Siu-Fai Lui, John E Sanderson.   

Abstract

This study was performed to determine whether the N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is a useful biomarker in predicting cardiovascular congestion, mortality, and cardiovascular death and event in chronic peritoneal dialysis (PD) patients. A prospective cohort study was conducted in 230 chronic PD patients in a dialysis unit of a university teaching hospital. Serum NT-pro-BNP was measured at baseline together with echocardiography and dialysis indices. Each patient was followed for 3 yr from the day of enrollment or until death. Time to develop first episode of cardiovascular congestion and other cardiovascular event and time to mortality and cardiovascular death were studied in relation to NT-pro-BNP. NT-pro-BNP showed the strongest correlation with residual GFR, followed by left ventricular ejection fraction and left ventricular mass index. In the univariate Cox regression model, NT-pro-BNP was a significant predictor of cardiovascular congestion, mortality, and cardiovascular death and event. In the fully adjusted multivariable Cox regression analysis that included residual GFR, left ventricular ejection fraction, and left ventricular mass index, the hazard ratios for cardiovascular congestion, mortality, composite end point of mortality and cardiovascular congestion, and cardiovascular death and event for patients of the fourth quartile were 4.25 (95% confidence interval [CI] 1.56 to 11.62; P = 0.005), 4.97 (95% CI 1.35 to 18.28; P = 0.016), 5.03 (95% CI 2.07 to 12.26; P < 0.001), 7.50 (95% CI 1.36 to 41.39; P = 0.021), and 9.10 (95% CI 2.46 to 33.67; P = 0.001), respectively, compared with the first quartile. These data showed that NT-pro-BNP is an important risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic PD patients and adds important prognostic information beyond that contributed by left ventricular hypertrophy, systolic dysfunction, and other conventional risk factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167121     DOI: 10.1681/ASN.2005121299

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  35 in total

1.  Can dialysis modality influence cardiovascular outcome?

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2012-06-03       Impact factor: 3.714

2.  Cardiorenal syndrome type 4: a review.

Authors:  Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2013-04       Impact factor: 2.041

Review 3.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

4.  Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.

Authors:  Angela Yee-Moon Wang; Fang Fang; John Chan; Yue-Yi Wen; Shang Qing; Iris Hiu-Shuen Chan; Gladys Lo; Kar-Neng Lai; Wai-Kei Lo; Christopher Wai-Kei Lam; Cheuk-Man Yu
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

5.  Relation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left atrial volume index to left ventricular function in chronic hemodialysis patients.

Authors:  Mayuko Yamazaki; Tetsuya Ogawa; Noriko Tamei; Yoshitaka Ando; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

6.  Delivering High-Quality Peritoneal Dialysis: What Really Matters?

Authors:  Isaac Teitelbaum
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

7.  B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis.

Authors:  Matthew A Roberts; Piyush M Srivastava; Neil Macmillan; David L Hare; Sujiva Ratnaike; Ken Sikaris; Francesco L Ierino
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

Review 8.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

9.  The association between left ventricular hypertrophy and biomarkers in patients on continuous ambulatory peritoneal dialysis.

Authors:  Sang-Ho Park; Se-Whan Lee; Seung-Jin Lee; Won-Yong Shin; Dong-Kyu Jin; Hyo-Wook Gil; Jong-Oh Yang; Eun-Young Lee; Sae-Yong Hong
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

10.  Biomarkers in predicting mortality and treatment in hemodialysis patients.

Authors:  Angela Yee-Moon Wang
Journal:  F1000 Med Rep       Date:  2009-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.